AgomAb Therapeutics

Franklin Rooseveltlaan 348 126

9000 Gent

BE

AgomAb Therapeutics

Foundation date

13/04/2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Upcoming events

Latest news

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    18 hours ago

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022

  • Pauwels Consulting takes over Science@Work

    Friday September 23rd 2022